BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Home
/
update
/
details

Immuneel Therapeutics Names Amit Mookim as New CEO

NextEdge Admin

06 Sep 2024

2 min 23 sec

Immuneel Therapeutics has appointed Amit Mookim as its new Chief Executive Officer. With over 20 years of experience in life sciences, technology, and private equity, Mookim will lead Immuneel’s mission to make advanced immunotherapy accessible to patients across India.

Mookim previously served as Managing Director for South Asia at IQVIA, a Fortune 500 leader in clinical research and technology. At IQVIA, he oversaw the operations of 20,000 professionals in India and played a pivotal role in integrating two large organizations post-merger, while driving commercial growth through organic development and acquisitions.

Mookim expressed his enthusiasm: “I’m thrilled to join Immuneel and contribute to its mission of advancing cell and gene therapy in India.” His leadership extends to his prior role at KPMG India, where he built the healthcare division, guiding hospitals, private equity funds, and international companies to expand in India.

He has also worked with the Indian government on public health initiatives like the Pradhan Mantri Jan Arogya Yojana (PMJAY) and advised key industry groups on healthcare innovation and pricing strategies.

Dr. Kiran Mazumdar-Shaw, Immuneel’s Co-founder, praised Mookim’s deep industry expertise, expressing confidence in his ability to propel the company forward. Co-founders Dr. Siddhartha Mukherjee and Dr. Kush Parmar welcomed his appointment, emphasizing his alignment with Immuneel’s goal to bring transformative immune cell therapies to India and beyond.

As CEO, Mookim will focus on expanding Immuneel’s reach, building partnerships, and scaling innovative therapies to meet local and global healthcare needs.